Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • SAPIEN 3
Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial
Posted inCardiology Clinical Updates news Specialties

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

Posted by MedXY By MedXY 09/07/2025
The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.
Read More
  • Beta-Cell Function, Not Glucagon, Predicts Glycemic Success: A Critical Analysis of the GRADE Study
  • Restoring Vision in Geographic Atrophy: Subretinal Photovoltaic Implants Achieve Significant Visual Gains in Landmark Clinical Trial
  • Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
  • Refining Prognosis in Anti-NMDAR Encephalitis: The NEOS2 Score Predicts Short- and Long-Term Recovery
  • EsoTIME: Precision Survival Prediction Replaces Traditional Staging for Resected Esophageal and Gastroesophageal Junction Cancers
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in